This video explains PCSK9 inhibitors' mechanism of action and the indications.

#PCSK9 inhibitors are monoclonal antibodies, that binds to PCSK9 protein, and inactivates it from binding to #LDL receptor. This step stops the LDL receptor destruction, and allows recycling of the LDL receptor. Thus helps in reducing the LDL level in the blood. LDL can be lowered 50 to 60% above that achieved by statin therapy alone.

Currently there are two FDA approved PCSK9 inhibitors, namely Evolocumab and Alirocumab.

Indications for PCSK9 inhibitors are.
Adult patients with familial #hypercholesterolemia.
Atherosclerotic cardiovascular disease, where an adequate LDL level with existing therapy is not achievable.
and in patients with statin intolerance.
#pharmacology

свернуть